Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | SMPD2 | O60906 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22064157 | 0.84 | AKT1 (0.35) | NPC1SMN1; SMN2 | |
| SCHEMBL22064188 | 0.83 | MAOB (0.40) | HDAC8HDAC6GRIK1GRIK2NPC1 | |
| SCHEMBL22063579 | 0.83 | NFE2L2 (0.51) | GRIK1GRIK2NPC1SMN1; SMN2 | |
| SCHEMBL22064154 | 0.81 | ALDH1A1 (0.45) | CYP1A2CYP2C19BACE1NPC1SMN1; SMN2 | |
| SCHEMBL22063783 | 0.80 | IDO1 (0.45) | NPC1 | |
| SCHEMBL22064190 | 0.79 | HDAC1 (0.46) | HDAC8GRIK1GRIK2CNR2 | |
| SCHEMBL28655523 | 0.76 | RXRA (0.47) | MTNR1AMTNR1BSMPD2HDAC8HDAC6 | |
| SCHEMBL28708757 | 0.76 | SMPD2 (0.56) | MTNR1AMTNR1BSMPD2HDAC8HDAC6 | |
| SCHEMBL22063766 | 0.75 | CYP4F2 (0.43) | SMN1; SMN2 | |
| SCHEMBL22064197 | 0.74 | HDAC3 (0.39) | HDAC8HDAC6NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691958-B2 | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | NORTHWESTERN UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691958-B2 | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | NORTHWESTERN UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
| US-11174238-B2 | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | NORTHWESTERN UNIVERSITY (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200181106-A1 | ENANTIOSELECTIVE CROSS DEHYDROGENATIVE COUPLING REACTIONS AND COMPOUNDS SYNTHESIZED BY THE REACTIONS | NORTHWESTERN UNIVERSITY (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691958-B2 | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | DUOX1, DUOX2, ALDH3A1 | MTNR1A 2669/4885MTNR1B 2050/4885SMPD2 4427/4885 |
| US-20200181106-A1 | ENANTIOSELECTIVE CROSS DEHYDROGENATIVE COUPLING REACTIONS AND COMPOUNDS SYNTHESIZED BY THE REACTIONS | DUOX1, DUOX2, ALDH3A1 | MTNR1A 2669/4885MTNR1B 2050/4885SMPD2 4427/4885 |
| US-11174238-B2 | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | DUOX1, DUOX2, ALDH3A1 | MTNR1A 2669/4885MTNR1B 2050/4885SMPD2 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.